目的 分析新型抗HER2药物德曲妥珠单抗(ENHERTU,DS-8201)治疗晚期乳腺癌患者的不良反应和生活质量情况.方法 回顾性分析2020年1月—2023年1月在解放军总医院第五医学中心接受DS-8201治疗的31例乳腺癌患者,对患者用药后的药品不良反应及患者的生活质量进行统计分析.结果 31例患者均出现不同程度的不良反应,其中Ⅲ级血液学毒性反应7例次,Ⅳ级血液学毒性反应3例次,发生率最高的不良反应为食欲下降和恶心,不良反应出现的时间为用药后的第2天,不良反应症状在第5天时最严重,第10天症状消失;用药后,患者的生命质量测定量表(Functional Assessment of Cancer Therapy-Breast,FACT-B)总分及生理状况、社会/家庭状况、情感状况、功能状况、附加关注等维度均高于治疗前,差异具有统计学意义(P<0.05).结论 DS-8201对患者的生活质量有积极影响,但也存在一些不良反应,应加强用药期间的不良反应监测.
Safety of transtuzumab deruxtecan in the treatment for late-stage breast cancer after multimodal therapies fail
Objective To analyze the adverse reactions and the life quality of patients with advanced breast cancer treated with a new type of anti-HER2 drugs,transtuzumab deruxtecan(ENHERTU,DS-8201).Methods 31 patients with breast cancer who had been treated with DS-8201 in the Fifth Medical Center of Chinese PLA General Hospital from January 2020 to January 2023 were retrospectively analyzed.Results All 31 patients experienced varying degrees of adverse reactions,including 7 cases of grade Ⅲ hematological toxicity and 3 cases of grade Ⅳ hematological toxicity.Most adverse reactions were loss of appetite and nausea,which occurred on the second day after medication,were the severest on the fifth day and disappeared on the tenth day.The physiological status,social/family status,emotional state,functional status and additional concern of patients as well as total score in the functional assessment of cancer therapy-breast(FACT-B)were higher than before administration,and the differences were statistically significant(P<0.05).Conclusion The use of DS-8201 had a positive impact on the life quality of patients,but there were also some adverse reactions.The monitoring of adverse reactions during medication should be strengthened in clinical practices.
Breast cancerAntibody-drug conjugateTranstuzumab deruxtecanAdverse drug reaction
万方数据
维普
